Thompson Reuters published a good overview of the challenges facing companies developing biosimilars. A few items which stood out for us were: Europe Has Led, But... - While 17…
A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The…
Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference. We will be there from Sunday evening through Wednesday afternoon. Look for us in PartneringOne,…
We’re actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: - Is currently involved in business development and licensing - Currently works for a pharma, biotech, VC, PE,…
This morning we learned that Sanofi is the winner in the "Where on Earth is the Partner for Afrezza?" sweepstakes. We'll defer to the many news outlets for…
Yes, and it might be worth it. Yesterday, Daiichi Sankyo announced an incredible $650 million deal with Florida-based Charleston Laboratories for the development and commercialization of a family of fixed…
Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In…
Do you know which are the top branded drug products in India? We didn't until we found this handy chart and article. We took their IMS data a step…
We're actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: Is currently involved in business development and licensing Currently works for a pharma, biotech, VC, PE, or consultancy Is…
A quick search resulted in several recent examples of US-based pharma companies executing “inversions” to reduce taxes via the acquisition of companies in Ireland: Salix merges with Cosmo Technologies, the…